Odyssey Therapeutics (ODTX)
Develops immune-signaling therapies for autoimmune and inflammatory diseases.
$26.90
Pre-market+0.28 (+1.07%)
At close$26.62(+8.63%)
In millions of USD, except per-share figures
| In millions | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|
| 40 | 55 | |
| Research & development | 32 | 36 |
| 7 | 11 | |
| General & administrative | 7 | 11 |
| Other expenses | 0 | 9 |
| Operating income | −40 | −55 |
| 2 | 3 | |
| Interest income | 2 | 3 |
| Interest expense | 0 | 0 |
| Other non-operating income | −2 | −3 |
| Income before tax | −38 | −53 |
| Income tax expense | 0 | 0 |
| Net income from continuing operations | −38 | −53 |
| Net income | −38 | −53 |
| EPS, basic | −$0.81 | −$1.74 |
| EPS, diluted | −$0.81 | −$1.74 |
| Weighted average shares, basic | 47 | 30 |
| Weighted average shares, diluted | 47 | 30 |
| EBITDA | −37 | −52 |
| Depreciation & amortization | 1 | 1 |
| EBIT | −38 | −53 |